Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro does not directly stop your period. There is no mechanism by which tirzepatide suppresses menstruation, and the clinical trials did not list absent periods as a direct side effect. What some women notice is a change in their cycle (timing, flow, or regularity) that is most likely linked to rapid weight loss and the hormonal shifts that accompany it, rather than the medicine itself. These medicines are prescription-only, and a GPhC-registered prescriber assesses your full picture before treatment begins. If your periods have stopped or changed significantly since starting Mounjaro, that is worth raising with your prescriber rather than assuming it will resolve on its own.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common misconception our prescribers encounter is that tirzepatide itself acts on the reproductive system. It doesn't. Mounjaro is a dual GIP and GLP-1 receptor agonist — it works on appetite signalling and blood-sugar regulation. Neither the Mounjaro SmPC nor the NHS medicines guidance for tirzepatide lists amenorrhoea (absent periods) as a recognised side effect of the drug itself.
What is documented, and what the clinical evidence supports, is that the weight loss Mounjaro produces can be substantial and relatively fast. In SURMOUNT-1, participants lost around 20–21% of body weight at the highest dose over 72 weeks. That scale of change, especially when it happens quickly, puts real pressure on the hormonal systems that govern the menstrual cycle. The effect is indirect, mediated by the body, not by the molecule.
So when someone asks whether Mounjaro can start or otherwise disrupt their period, the honest answer is: the medicine is unlikely to be the direct cause, but the weight changes it drives almost certainly can affect cycle regularity. That distinction matters for how you respond to it.
The menstrual cycle is sensitive to energy availability. When the body senses a significant calorie deficit or rapid reduction in fat stores, it can downregulate the hypothalamic-pituitary-ovarian axis, the hormonal chain that triggers ovulation. This is sometimes called functional hypothalamic amenorrhoea, and it is well recognised in contexts ranging from rapid weight loss to intensive athletic training.
Body fat also stores and produces oestrogen. A meaningful reduction in fat mass changes the body's circulating oestrogen profile, which can delay, lighten or temporarily suppress menstruation. This is not unique to tirzepatide, it can happen with any approach that drives significant weight change. You can read more about how tirzepatide produces these changes on our tirzepatide information page.
The NHS notes that weight management medicines work best alongside lifestyle changes, and the interaction between diet, activity and hormonal health is complex. If you are eating significantly less since starting treatment, the calorie reduction itself (quite separate from the medicine) may be a contributing factor. A change that settles as your weight stabilises is different from one that persists or worsens, and the NHS weight-management guidance recommends discussing ongoing menstrual changes with a clinician rather than waiting them out. The NHS's patient information on tirzepatide is a useful starting point.
There is one scenario that must not be overlooked: pregnancy. Mounjaro is not recommended during pregnancy, and if your period is late or has stopped, ruling out pregnancy is the first step, not the last. This is not a remote concern: how Mounjaro affects your period includes the important fact that some women experience improved fertility as they lose weight on treatment, sometimes before they expect it.
The MHRA advises that women of childbearing age use effective contraception while taking tirzepatide. If you take the oral contraceptive pill, note that NHS guidance recommends adding a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because the slower gastric emptying tirzepatide causes may reduce pill absorption. Information about taking Mounjaro during your period covers this in more detail.
Beyond pregnancy, a period that stops entirely for more than a couple of months, or that changes dramatically in character, is worth a GP review regardless of what else is happening. Other causes (thyroid conditions, polycystic ovary syndrome, stress) are unrelated to Mounjaro but may coincide with starting treatment, and they deserve their own assessment.
First, do not stop Mounjaro without speaking to your prescriber. A change in your cycle is not a reason to discontinue treatment, but it is a reason to have a conversation. Note when the change started, whether it correlates with a dose increase (the link between dose changes and cycle timing is worth understanding), and how significant the change is.
Many women find that cycle irregularity settles once their weight stabilises, the body adjusts to its new set point and hormonal patterns reestablish themselves. Others find that the change persists and warrants investigation. Either way, the right step is the same: raise it.
If you started Mounjaro through a service that does not offer ongoing clinical support, that gap matters. At nume, aftercare is available seven days a week, and every repeat prescription involves a clinical re-review. If you have questions about how treatment is affecting you, our team is contactable directly. And if you are weighing up the broader picture of starting treatment, including what a full consultation involves, speaking to our prescribers is the place to start.
The MHRA's Yellow Card scheme allows patients to report any suspected side effect, including unexpected menstrual changes, a useful route if you want it formally recorded.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.